Brief: HLB Inc Q2 Operating Profit Likely 13 Billion Won, Turns To Profit From Year Earlier
20/07/2022 08:20
July 20 (Reuters) - HLB Inc 028300.KQ :
* Q2 OPERATING PROFIT LIKELY 13 BILLION WON, TURNS TO PROFIT
FROM
YEAR EARLIER
Further company coverage: 028300.KQ
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on HLB
See all newsBrief: Hlb Co Resubmits New Drug Application Of Rivoceranib To Us FDA
Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns (updated)
Brief: Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Brief: Elevar Therapeutics Resubmits NDA To U.S. FDA For Camrelizumab Plus Rivoceranib Astreatment For Unresectable Hepatocellular Carcinoma
Brief: Hlb Inc To Acquire 16 Billion Won Worth Of Shares In Neurotobe Pharmaceuticals Inc